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Abstract
Introduction: Malignant pleural mesothelioma is a rare tumour with a bad prognosis. The only consensual prognostic factors are repre-
sented by the stage and the histologic type. Concerning the histologic type, epithelioid mesothelioma is known to have better prognosis 
in comparison with the sarcomatoid and biphasic types. Epithelioid mesotheliomas have been reported to be a heterogeneous progno-
stic group. Our aim was to assess the impact on the survival of different characteristics of epithelioid mesothelioma, including nuclear 
atypia, mitotic count, MIB-1 index, inflammatory host response, stromal desmoplasia, necrosis, vascular emboli and invasion depth.
Material and methods: We performed a study of survival of 30 malignant pleural mesotheliomas according to the different 
parameters studied. 
Results: The study included 26 women and 4 men. The mean age of the patients was 61 years. The microscopic exam concluded 
to an epithelioid mesothelioma in 17 cases, sarcomatoid mesothelioma in 4 cases and biphasic mesothelioma in 9 cases. The 17 
cases of epithelioid mesothelioma developed severe nuclear atypia in 6 cases and mild nuclear atypia in 11 cases. The mitotic 
count and the MIB-1 score were respectively inferior to 5 mitoses/50 HPF and inferior to 10% in 11 cases and were superior to 
5 mitoses/50 HPF and superior to 10% in 6 cases. No vascular emboli were recorded. Tumour necrosis was reported in 1 case. 
The inflammatory host response was severe in 4 cases and mild in 13 cases. The tumoral stroma was desmoplastic in 4 cases. 
The invasion depth was superior to 0.5mm in 16 cases. The median overall survival amounted to 180 days. Nuclear atypia was 
the only feature that had impact on survival in the group of epithelioid mesothelioma. 
Conclusion: Our results highlight the correlation of nuclear atypia with survival. 
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Introduction
Malignant pleural mesothelioma (MPM) is 
a rare tumour accounting for 2% of all pleural 
tumours with a bad prognosis. Its management 
has been improved by the emergence of new the-
rapeutic modalities, including immunotherapy. 
The most relevant prognostic factors are repre-
sented by the tumour stage and the histologic 
type. Many modifications have been made in the 
field of staging of mesothelioma in order to assess 
a more accurate prognostic category. In fact, some 
authors reported that the prognostic impact of the 
6th and 8th AJCC editions was insufficient [1]. 
Concerning the typing of mesothelioma, 2 major 
groups were identified in the 2015 World Health 
Organization classification including locali-
sed and diffuse mesothelioma [2]. Each group 
contains epithelioid, sarcomatoid and biphasic 
mesothelioma. Epithelioid mesotheliomas have 
better prognosis. Among this group, many authors 
reported an important prognostic heterogeneity. 
This fact made the researchers look for other pro-
gnostic factors necessary in that group [3]. Many 
authors reported the nuclear grade and necrosis as 
prognostic factors [4]. Our aim was to assess the 
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impact on the survival of different characteristics 
of epithelioid mesothelioma, including nuclear 
atypia, mitotic count, MIB-1 index, inflammatory 
host response, stromal desmoplasia, necrosis, 
vascular emboli and invasion depth.
Material and methods
We conducted a  retrospective study of 30 
MPM diagnosed over a 20-year period (1995–
2015). We included only patients with complete 
records, including clinical, radiologic and micro-
scopic features. 
1. Standard techniques: All the samples were 
performed after a certain delay of fixation (8 
hours for biopsies and 24 hours for surgical 
specimen). 
2. Immunohistochemical technique: Different 
techniques were applied manually. The 
used diagnostic antibodies were as follows: 
anti-calretinin (clone CAL 6, Leica, diluted 
at 1:200), anti-Epithelial Membrane Anti-
gen (EMA)  (clone GP1.4, Leica, diluted at 
1:100), anti-mesothelin (clone 5B2, Biogenex, 
ready-to-use), anti-Thyroid Transcription 
Factor 1 (TTF1) (clone SPT24, Leica, diluted 
at 1:100), anti-ACE (clone 12.140.2, Leica, 
diluted at 1:200), anti-cytokeratin (clones 
AE1 and AE3 mixed to a ratio 20:1, diluted 
at 1:100), anti-vimentin (clone V9, Leica, 
diluted at 1:800), anti-CD15 (clone Carb-1, 
Leica, ready-to-use), anti-cytokeratin 5/6 
(clone CK5/6.007, Biocare, diluted at 1:100), 
anti-bcl2 (clone bcl 2/100/D5, Leica, diluted 
at 1:100), anti-CD99 (clone PCB1, Leica, dilu-
ted at 1:100) and anti-CD34 (clone QBEnd10, 
Dako, diluted at 1:25). The scoring of MIB-1 
was performed using an anti-Ki67 antibody 
(clone MIB-1, Immunotech, Westbrook, ME, 
USA, diluted at 1:100).
Microscopic diagnosis: All the microscopic 
diagnoses were reviewed by 2 pathologists (MM, 
FM). A mean of 12 slides per case were re-exa-
mined. The diagnosis was based on the 2015 
WHO classification [2]. In the group of epithe-
lioid and biphasic mesotheliomas, we assessed 
prognostic criteria reported by Krasinskas M. 
and colleagues [5].
Nuclear atypia (severe/mild): nuclear fe-
atures were evaluated using high-power field 
(HPF) at x400 magnification using an Olympus 
SX41 microscope (Olympus, Tokyo, Japan) with 
an eyepiece of 22 mm diameter (Fig. 1A, B). 
Mitotic count (high/low): it was evaluated after 
scanning through all tumour slides and counted 
as an average of mitotic figures per 50 high-po-
wer fields. The cut-off of 5 mitoses was chosen. 
MIB-1 scoring: MIB-1 index was recorded as the 
percentage of tumour cells with positive nuclear 
immunostaining. A  cut-off of 10% was used. 
Desmoplastic stroma: present or absent (Fig. 1C). 
Vascular emboli: present or absent. Inflammatory 
host response: It was evaluated as mild to mo-
derate or severe (Fig. 1D, E). Histologic subtype: 
The following 5 histologic patterns were recorded 
in 5% increments: tubulo-papillary, trabecular, 
micro-papillary, solid and pleomorphic. Only 3 
patterns were observed in our study: the tubulo
-papillary growth pattern consisting of tubules 
associated to papillary structures (Fig. 1F), the 
trabecular pattern composed of thin cords of 
tumour cells (Fig. 1G) and solid pattern made 
up of nests of tumour cells (Fig. 1 H). Necrosis: 
present or absent. The depth of invasion: It was 
evaluated as superficial or deep with a cut-off of 
0.5 mm.
A  review of the literature was performed 
on PubMed (http://www.ncbi.nih.gov/pubmed), 
Google and Google Scholar using the following 
keywords: malignant mesothelioma, pleural 
mesothelioma, epithelioid mesothelioma, desmo-
plastic mesothelioma, biphasic mesothelioma, 
sarcomatoid mesothelioma.
Statistical analysis
The different mean/median survival and the 
survival curves were represented using SPSS 
statistics 23. The comparison of the survival cu-
rves was made using the logRank. The mean of 
survival was estimated as the interval between the 
date of diagnosis and the date of death or a point 
date fixed for 15th March 2018.
Results
Epidemiologic and clinical characteristics
The mean age of the patients was 61 years, 
average 22 to 80 years. The sex ratio (M/F) was 6.5. 
Asbestos exposure was reported in 21 cases. The 
most frequent symptom was chest pain reported 
in 25 cases. Physical exam was normal in 9 cases. 
It revealed a pleural syndrome in most patients 
(60%). Imaging findings consisted mainly in dif-
fuse pleural thickening in 17 cases. The tumours 
were classified as stage I in 12 cases, stage II in 3 
cases, stage III in 14 cases and stage IV in 1 case. 
Needle pleural biopsy was performed in 18 cases. 
In the other cases, the biopsy was performed thro-
ugh thoracoscopy in 16 cases and thoracotomy in 
3 cases. It allowed the diagnosis in respectively 7 
Advances in Respiratory Medicine 2019, vol. 87, no. 2, pages 90–95 
92 www.journals.viamedica.pl
Figure 1. A — mild nuclear atypia in epithelioid malignant mesothe-
lioma (HE × 200); B — severe nuclear atypia in epithelioid malignant 
mesothelioma (HE × 400); C — desmoplastic stroma in an epithe-
lioid malignant mesothelioma (HE × 200); D — mild inflammatory 
host response in an epithelioid malignant mesothelioma (HE × 200); 
E — severe inflammatory host response in an epithelioid malignant 
mesothelioma (HE × 200); F — papillary epithelioid mesothelioma 
(HE × 200); G — trabecular epithelioid mesothelioma (HE × 200); 
H — solid epithelioid mesothelioma (HE × 200) 
cases/18, 16 cases/16 and 3 cases/3. A lymph node 
biopsy was performed through mediastinoscopy 
in one case and yielded the diagnosis. The diagno-
sis was made on surgical specimen in 2 patients: 
one bullectomy and one right upper lobectomy. 
The Table 1 summarises the epidemiologic and 
clinical features. 
Microscopic features
The microscopic exam concluded to an 
epithelioid mesothelioma (EM) in 17 cases, 
sarcomatoid mesothelioma (SM) in 4 cases and 
biphasic mesothelioma (BM) in 9 cases. The 17 
cases of EM presented severe nuclear atypia 
in 6 cases and mild nuclear atypia in 11 cases 
(Fig 1A, B). The mitotic count and the MIB-1 
score were respectively inferior to 5 mitoses/50 
high power fields and inferior to 10% in 11 cases 
and were superior to 5 mitoses/50 high power 
fields and superior to 10% in 6 cases. No vasular 
emboli were recorded. Tumour necrosis was re-
ported in 1 case. The inflammatory host response 
was severe in 4 cases and mild in 13 cases. The 
tumoral stroma was desmoplastic in 4 cases. 
The invasion depth was superior to 0.5 mm in 
16 cases. The Table 2 illustrates the microscopic 
characteristics of the 17 EM.
Follow-up
Fifteen patients were lost of view after a mean 
follow-up period of 2.8 months. Thirteen subjects 
died before or during the treatment after a mean 
follow-up period of 6.6 months. One patient had 
a sarcomatoid localised mesothelioma diagnosed 
on a bullectomy. He developed no complications 
after a follow-up period of 11 years. One person 
was treated surgically and suffered from bone 
metastases after a follow-up period of 4 months.
Survival study
The median overall survival amounted to 180 
days, 95%CI [63–296] (Fig. 2A)
The median overall survival was estimated 
at 365 days in stage 1a, 210 days in stage 1b, 60 
days in stage 2, 365 days in stage 3a, 180 days 
in stage 3b and 90 days in stage 4 (p = 0.423). 
The survival rate was estimated at 66% at 
4 months, in comparison to 0% at 3 months in 
stage 2. 0% at 4 months in stage 3 and 0% at 
3 months in stage 4.
The different characteristics assessed in EM 
were as follows.
Nuclear atypia: The median survival was es-
timated at 210 days, CI95% [0–431] in mild cases 
and 365 days, CI95%[36-383] in severe cases. 
A significant statistical difference was reported 
between both groups (p = 0.045) (Fig. 2B)
Mitotic count: The median survival of pa-
tients with high grade was 210 days, CI95% 
[0–427] and 365 days in the low-grade group, 
CI95% [536–383]. There was no statistical dif-
ference between both curves (p = 0.248). 
MIB-1 index: The median survival was esti-
mated respectively at 210 days in high- grade gro-
up IC95% [0–427] and 365 days IC95% [536–383] 
in low-grade group. There was no statistical diffe-
A B
C D
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Table 1. Patients’ characteristics
Age Mean: 61 years [22–80 years]
Sex 26M/4W
Smoking 17 patients
Asbetos 21 patients
Symptoms 29 patients symptomatic: chest pain: 25 cases (83.3%) 
Imaging Chest-x-Ray
Pleural opacity: 27 cases (90%)
Pleural thickening: 2 cases (6.7%)
Pneumothorax: 1 case 
Associated to:
Cardiomegaly (1 case), right mediastinal opacity (1 case), reticulo-nodular infiltration  
(1 case), costal lysis (1 case), alveolar opacity (1 case) 
CT-scan
Diffuse pleural thickening: 17 cases (56.7%), tissular mass: 5 cases (16.5%), pleural fluid: 
19 cases (63.4%), mediastinal adenomegaly: 5 cases (16.7%), atelectasis: 5 cases (16.7%), 
pleural nodules: 4 cas (13.3%), parenchymal condensation: 2 cases (6.7%)
Stages 9 stage IA, 3 stage IB, 3 stage II, 14 stage IIIB, 1 stage IV 
Means of diagnosis Pleural cytology: 7+/18, Needle pleural biopsy: 7+/18, pleuroscopy: 1+/1, thoracoscopy: 
16+/16, thoracotomy: 3+/3, mediastinoscopy:1+/1
Microscopic diagnosis 17 EM, 4 SM et 9 BM
TT and follow-up Surgical resection: 2 cases. 11 talc pleurodesis + chemo ± radiation therapy: 14 cases 
15 lost of view
median survival: 180 days 
EM: epithelioid mesothelioma; SM: sarcomatoid mesothelioma; BM: biphasic mesothelioma
     
Table 2. Microscopic characteristics of the epithelioid 
mesotheliomas
Microscopic features Number of cases
Nuclear atypia Severe: 6 cases
Mild: 11 cases
Mitotic count < 5 mitoses/50HPF: 11 cases
> 5 mitoses/50HPF: 6 cases
MIB-1 index < 10%: 11 cases
> 10%: 6 cases
Vascular emboli 0
Inflammatory host response Severe: 4 cases
Mild: 13 cases
Desmoplastic stroma 4 cases
Depth invasion > 0.5 mm: 16 cases
Necrosis 1 case
rence between both curves (p = 0.248) (Fig. 2C). 
The 4-month survival was estimated at 25% in 
the group with low mitotic index in comparison 
to 16% in the group with high index.
Histologic subtype: EM was classified into 
trabecular subtype in 5 cases, tubulo-papillary 
subtype in 9 cases and solid subtype in 5 cases. 
There was no significant difference between all 
curves (p = 0.05) (Fig. 2D). In tubulopapillary 
and trabecular subtypes, we noticed a survival 
at 2 months of respectively 0 and 40%.
Necrosis: Necrosis was present in 1 case. The 
survival curves showed no significant statistical 
difference (p = 0.6).
Invasion depth: The invasion thickness 
was inferior to 0.5 mm in 2 cases and superior 
to 0.5 mm in 17 cases. The survival curves 
presented no significant statistical difference 
(p = 0.05).
Inflammatory host response: The mean survi-
val in the group with discrete to mild reaction 
and the group with severe reaction was estimated 
respectively at 233 days, 95%CI [137–329] and 
142 days, 95%CI [78–206] (p = 0.9). The survival 
was estimated at 40% at 3 months in the group 
with mild to moderate reaction in comparison to 
25% in the group with severe reaction.
Desmoplastic stroma: The mean survi-
val of patients developing tumours without 
desmoplastic stroma and with desmoplastic 
stroma accounted respectively for 271 days, 
95%CI [184–357] and 172 days, 95%CI [82–262] 
(p = 0.686). 
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the worse prognostic impact of pleomorphic 
subtype in comparison with the other subtypes, 
including tubulopapillary, papillary, micropapil-
lary, trabecular, solid, and pleomorphic. In our 
study, the prognostic impact of the histologic 
subtype was not assessed because of the cros-
sing survival curves. The only reported subtypes 
were solid, tubulopapillary and trabecular. All 
solid subtypes were lost of view but concerning 
tubulopapillary and trabecular subtypes, we 
noticed a survival at 2 months of respectively 0 
and 40%. Prognostic impact of histologic sub-
types has to be assessed in teams trained in the 
diagnosis of MPM. This is due to variable repro-
ducbility of subtyping reported in the literature. 
In fact, some authors noted a strong reproduci-
bility with good agreement and others described 
moderate to substantial agreement [8, 9]. In 
a multi-institutional study, Rosen L. et al. [4], 
assessed three grading systems consisting in the 
association of nuclear grade and mitotic count, 
nuclear grade and necrosis and mitotic count 
and necrosis [4]. They reported that the nuclear 
grade predicts survival in epithelioid mesothe-
lioma and that necrosis helps to stratify overall 
survival. In our study, we tried to establish the 
prognostic impact of vascular emboli, invasion 
Figure 2. A — survival curve of the 30 patients included in the study; B — survival curves according to the nuclear atypia (p = 0.045); C — survival 
curves according to the MIB-1 index (p = 0.248); D — survival curves according to the histologic subtype (p = 0.05)
Discussion
In the study, the authors aimed to assess the 
prognostic impact of some microsocpic features 
in epithelioid mesothelioma. Nuclear atypia was 
the only feature that had prognostic impact. This 
fact has to be taken with caution because of the 
important number of lost of view cases in the stu-
dy. Prognostic factors of MPM have been widely 
discussed in the literature with varying results 
and some similarities. Nuclear atypia has been 
reported as a prognostic factor by some authors 
and has been integrated into a nuclear grade in 
association with mitotic atypia by others [4]. 
Wang et al. [6], published a nomogram to predict 
prognosis in malignant pleural mesothelioma. 
The nomogram integrated the age, race, histo-
logy type, T stage, M stage, surgical resection 
and chemotherapy as independent prognostic 
factors. The stage has been reported as the most 
reliable prognostic factor. In our study, the pro-
gnostic impact of stage wasn’t assessed but we 
noticed that in stage 1, the survival was estima-
ted at 66% at 4 months, in comparison to 0% at 
3 months in stage 2, 0% at 4 months in stage 3 
and 0% at 3 months in stage 4. In the 2015 WHO 
classification of MPM, Kadota et al. [7] reported 
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thickness and necrosis but we didn’t reach an in-
terpretable result because of the absence of both 
criteria in almost all cases. Concerning the host 
reaction, we didn’t assess a prognostic impact 
but we noticed that the survival was estimated 
at 40% at 3 months in the group with mild to 
moderate reaction in comparison to 25% in the 
group with severe reaction. Concerning mitotic 
index, we also noted that the 4-month survival 
was estimated at 25% in the group with low 
index in comparison to 16% in the group with 
high index. This tendency was also observed for 
mitotic index. In fact, the 4-month survival was 
estimated at 25% in the group with low mitotic 
index in comparison to 16% in the group with 
high index. Concerning desmoplastic stroma, we 
noticed that the 4-month survival was estimated 
at 20% in the group without desmoplastic stroma 
in comparison to 25% in the group with desmo-
plastic stroma. 
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